Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 9Lymphoma, Follicular 4Recurrence 3Lymphoma, B-Cell 3Neoplasms, Plasma Cell 2Burkitt Lymphoma 2Spondylolisthesis 1Spinal Stenosis 1Spinal Cord Neoplasms 1Smoldering Multiple Myeloma 1Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphedema 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hodgkin Disease 1Failed Back Surgery Syndrome 1Disease Progression 1Disease 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Transplantation, Autologous × Clear all
NCT02244125 2025-11-24

PCD

Institut Curie

Phase 2 Completed
100 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00950768 2009-08-03

Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients

Azienda Ospedaliera San Giovanni Battista

Phase 3 Completed
298 enrolled
Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡